ANL (Adlai Nortye) Other Long Term Assets: $0.28 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANL Adlai Nortye Ltd ANL
8 GF Score
Price $15.57
! 8 Warning Signs
View Full Analysis

What is Adlai Nortye Other Long Term Assets?

Adlai Nortye ANL -1.33% 8 Other Long Term Assets is $0.28 Mil as of Jun. 2026. GuruFocus rates ANL with a GF Score™ of 8/100. The stock has 8 warning signs investors should review.

Adlai Nortye's other long-term assets for the quarter that ended in Jun. 2026 was $0.28 Mil.

Adlai Nortye's quarterly other long-term assets increased from Jun. 2025 ($0.23 Mil) to Dec. 2025 ($0.25 Mil) and increased from Dec. 2025 ($0.25 Mil) to Jun. 2026 ($0.28 Mil).

Adlai Nortye's annual other long-term assets increased from Dec. 2023 ($0.28 Mil) to Dec. 2024 ($0.30 Mil) but then declined from Dec. 2024 ($0.30 Mil) to Dec. 2025 ($0.25 Mil).

Adlai Nortye Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Other Long Term Assets Chart

Adlai Nortye Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial 0.45 0.33 0.28 0.30 0.25

Adlai Nortye Semi-Annual Data
Jun25 Dec25 Jun26
Other Long Term Assets 0.23 0.25 0.28
ANL
8GF Score
Adlai Nortye Ltd ANL
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adlai Nortye Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $0.28 Mil mean?
Adlai Nortye (ANL) has a Other Long Term Assets of $0.28 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Adlai Nortye and its competitors.
Is Adlai Nortye's Other Long Term Assets too high?
Adlai Nortye's current Other Long Term Assets is $0.28 Mil. Overall, Adlai Nortye has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Adlai Nortye's Other Long Term Assets compare to TBPH and ACRS?
Adlai Nortye's Other Long Term Assets of $0.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Other Long Term Assets is $0.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Other Long Term Assets of $0.28 Mil. The current Other Long Term Assets is $0.28 Mil. Adlai Nortye's overall GF Score™ is 8/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Other Long Term Assets is $0.28 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
8GF Score

Get the complete analysis for ANL

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.57
Price